Efficiency of local BCNU in newly diagnosed and recurrent glioblastoma and MGMT promoter methylation
Gutenberg, A.Bock, H.C.Rohde, V.Reifenberger, G.Giese, A.
Abstract
Objective: There is reason to believe that alternative dose-dense schedules may overcome resistance in patients with an unmethylated MGMT promoter. Carmustine (BCNU) is a nitrosourea derivate which alkylates DNA and RNA, but it does not render cells cross resistant to other alkylators and therefore [for full text, please go to the a.m. URL]
Metrics
Topics
Related Documents
Radiomics and MGMT promoter methylation for prognostication of newly diagnosed glioblastoma
Takahiro SasakiManabu KinoshitaKoji FujitaJunya FukaiNobuhide HayashiYuji UematsuYoshiko OkitaMasahiro NonakaShusuke MoriuchiTakehiro UdaNaohiro TsuyuguchiHideyuki AritaKanji MoriKenichi IshibashiKoji TakanoNamiko NishidaTomoko ShofudaEma YoshiokaDaisuke KanematsuYoshinori KodamaMasayuki ManoNaoyuki NakaoYonehiro Kanemura
MGMT promoter methylation in prognosis of patients with newly diagnosed IDH1 wildtype Glioblastoma
PV-0503: Novel RPA classification combining MGMT promoter methylation status in newly diagnosed glioblastoma
Chan Woo WeeE. KimI.A. KimT.M. KimY.J. KimC.K. ParkJ.W. KimC.Y. KimSerah ChoiJ.H. KimS.H. ParkGheeyoung ChoeS.T. LeeI.H. Kim
Topographical Mapping of 436 Newly Diagnosed IDH Wildtype Glioblastoma With vs. Without MGMT Promoter Methylation
Fatih IncekaraSebastian R. van der VoortHendrikus J. DubbinkPeggy N. AtmodimedjoRishi Nandoe TewarieGeert J. LycklamaArnaud J.P.E. VincentJohan M. KrosStefan KleinMartin J. van den BentMarion Smits
PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation
Heinrich ElinzanoMichael GlantzMaciej MrugalaSantosh KesariDavid PiccioniLyndon KimEdward PanShakeeb YunusThomas CoyleTimothy KinsellaDevon EvansKalyan MantripragadaJerrold L. BoxermanThomas A. DiPetrilloJohn E. DonahueNicholas HebdaKristen MitchellKayla RosatiHoward Safran